➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,984,403

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,984,403 protect, and when does it expire?

Patent 6,984,403 protects ZMAX and is included in one NDA.

This patent has fifty patent family members in forty-three countries.

Summary for Patent: 6,984,403
Title:Azithromycin dosage forms with reduced side effects
Abstract:The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.
Inventor(s): Hagen; Timothy A. (East Lyme, CT), Lo; Julian B. (Old Lyme, CT), Thombre; Avinash G. (East Lyme, CT), Herbig; Scott M. (East Lyme, CT), Appel; Leah Elizabeth (Bend, OR), Crew; Marshall David (Bend, OR), Friesen; Dwayne Thomas (Bend, OR), Lyon; David Keith (Bend, OR), McCray; Scott Baldwin (Bend, OR), West; James Blair (Bend, OR)
Assignee: Pfizer Inc. (New York, NY)
Application Number:10/763,340
Patent Claim Types:
see list of patent claims
Dosage form; Use; Composition;

Drugs Protected by US Patent 6,984,403

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv ZMAX azithromycin FOR SUSPENSION, EXTENDED RELEASE;ORAL 050797-001 Jun 10, 2005 DISCN Yes No   Start Trial   Start Trial Y METHOD OF TREATING BACTERIAL INFECTIONS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,984,403

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2218   Start Trial
Argentina 045630   Start Trial
Austria 407663   Start Trial
Australia 2004216676   Start Trial
Brazil PI0403935   Start Trial
Canada 2467611   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.